surepath liquid‐based medium (Becton Dickinson)
90
Structured Review
Becton Dickinson
surepath liquid‐based medium
Surepath Liquid‐Based Medium, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/surepath+liquid-based+medium/surepath+medium/pmc07689747-53-5-8
Average 90 stars, based on 1 article reviews
Surepath Liquid‐Based Medium, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/surepath+liquid-based+medium/surepath+medium/pmc07689747-53-5-8
Average 90 stars, based on 1 article reviews
surepath liquid‐based medium - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Does high-risk human papilloma virus genotyping of abnormal anal cytology improve detection of high-grade anal intraepithelial neoplasia? Article Snippet: 2213-2945/$36 2014 American Society http://dx.doi.org/10.1016/j.jasc.2014.03.0 Article Title: Efficacy of thermoablation in treating cervical precancerous lesions in a low-resource setting Article Snippet: Cervical specimens were collected using a broom-like device and fixed in BD SurePath liquid medium (Becton Dickinson, Franklin Lakes, NJ, USA). Article Title: HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. Article Snippet: Randomized clinical trials using human papillomavirus (HPV) DNA testing have found increased protection against cervical cancer and HPV-based screening is globally recommended for women ≥30 years of age.. HPV-mRNA is a promising alternative target for cervical screening tests, but assessing equivalence requires longitudinal evaluation over at least the length of a screening interval.. Our aim is to analyse the longitudinal sensitivity of HPV-mRNA and HPV-DNA in cervical samples taken up to 7 years before severe cervical intraepithelial neoplasia or worse (CIN 3+). Article Title: Prevalence of high‐risk human papillomavirus after HPV ‐vaccination in Denmark Article Snippet: Samples were clinician collected in Article Title: Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study Article Snippet: Article Title: p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping. Article Snippet: The cervical samples were collected from all patients once on the Concentration Assay:Article Title: The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. Article Snippet: .. This reconstitution protocol was developed with the assistance of |